Terms: = Ovarian cancer AND ERCC5, XPGC, 2073, ENSG00000134899, RP11-484I6_5, COFS3, XPG, UVDR, ERCM2 AND Prognosis
2972 results:
1. Transcript and protein signatures derived from shared molecular interactions across cancers are associated with mortality.
Zhao Y; Li X; Loscalzo J; Smelik M; Sysoev O; Wang Y; Mahmud AKMF; Mansour Aly D; Benson M
J Transl Med; 2024 May; 22(1):444. PubMed ID: 38734658
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic factors and the role of primary debulking in operable stage IVB ovarian cancer with supraclavicular lymph node metastasis: a retrospective study in Chinese patients.
Quan C; Chen X; Wen H; Wu X; Li J
BMC Cancer; 2024 May; 24(1):565. PubMed ID: 38711015
[TBL] [Abstract] [Full Text] [Related]
3. Germline biallelic BRCA2 pathogenic variants and medulloblastoma: an international cohort study.
Kastellan S; Kalb R; Sajjad B; McReynolds LJ; Giri N; Samuel D; Milde T; Elbracht M; Holzhauer S; Niewisch MR; Kratz CP
J Hematol Oncol; 2024 Apr; 17(1):26. PubMed ID: 38685107
[TBL] [Abstract] [Full Text] [Related]
4. Cardiovascular mortality risk in patients with ovarian cancer: a population-based study.
Hu ZL; Yuan YX; Xia MY; Li Y; Yang Y; Wang SN; Meng XZ; Sun MY; Wang N
J Ovarian Res; 2024 Apr; 17(1):88. PubMed ID: 38664732
[TBL] [Abstract] [Full Text] [Related]
5. Mechanism of single-stranded DNA annealing by RAD52-RPA complex.
Liang CC; Greenhough LA; Masino L; Maslen S; Bajrami I; Tuppi M; Skehel M; Taylor IA; West SC
Nature; 2024 May; 629(8012):697-703. PubMed ID: 38658755
[TBL] [Abstract] [Full Text] [Related]
6. A novel TCGA-validated programmed cell-death-related signature of ovarian cancer.
Cai X; Lin J; Liu L; Zheng J; Liu Q; Ji L; Sun Y
BMC Cancer; 2024 Apr; 24(1):515. PubMed ID: 38654239
[TBL] [Abstract] [Full Text] [Related]
7. Machine learning developed a fibroblast-related signature for predicting clinical outcome and drug sensitivity in ovarian cancer.
Fu W; Feng Q; Tao R
Medicine (Baltimore); 2024 Apr; 103(16):e37783. PubMed ID: 38640321
[TBL] [Abstract] [Full Text] [Related]
8. Immunotherapy combined with targeted therapy in advanced small cell carcinoma of the ovary of hypercalcemic type: A case of overall survival lasting for over 5 years.
Gao Y; Zang L; Ye Y; Ma F; Kang M; Zheng K; Kang Y; Wang H; Xu C
Eur J Obstet Gynecol Reprod Biol; 2024 Jun; 297():270-274. PubMed ID: 38604920
[TBL] [Abstract] [Full Text] [Related]
9. Development and validation of an ultrasound-based deep learning radiomics nomogram for predicting the malignant risk of ovarian tumours.
Du Y; Xiao Y; Guo W; Yao J; Lan T; Li S; Wen H; Zhu W; He G; Zheng H; Chen H
Biomed Eng Online; 2024 Apr; 23(1):41. PubMed ID: 38594729
[TBL] [Abstract] [Full Text] [Related]
10. Characteristics of patients with late recurrence endometrial cancer.
Çakır İ; Gülseren V; Özdemir İA; Abacı H; Talu ECK; Çakır ZE; Ata C; Kuru O; Gökçü M; Sancı M; Güngördük K
J Cancer Res Ther; 2024 Jan; 20(1):232-237. PubMed ID: 38554326
[TBL] [Abstract] [Full Text] [Related]
11. [Clinical analysis of 12 cases of ovarian yolk sac tumor].
Liu J; Chu HJ; Shan YP; Song WJ; Chen AP
Zhonghua Fu Chan Ke Za Zhi; 2024 Mar; 59(3):210-214. PubMed ID: 38544450
[No Abstract] [Full Text] [Related]
12. Frizzled class receptor 5 contributes to ovarian cancer chemoresistance through aldehyde dehydrogenase 1A1.
Xia Y; Wang S; Sun Y; Wang W; Chang S; Zhang Z; Zhao C
Cell Commun Signal; 2024 Mar; 22(1):194. PubMed ID: 38539211
[TBL] [Abstract] [Full Text] [Related]
13. PURE vs. mixed clear cell ovarian carcinomas: Is there any impact on survival?
Güzel D; Terek C; Besler A; Serin G; Önal Z; Akman L; Göker E; Ali Şanli U; Zekioğlu O; Özdemir N; Özsaran A; Yildirim N
Eur J Obstet Gynecol Reprod Biol; 2024 May; 296():321-326. PubMed ID: 38518487
[TBL] [Abstract] [Full Text] [Related]
14. Association of tet methylcytosine dioxygenase 2 and 5-hydroxymethylcytosine in endometrioid adenocarcinoma and its clinical significance.
Kuang L; Zhang J; Li Y; Wang Q; Liu J; Zhang B
BMC Womens Health; 2024 Mar; 24(1):188. PubMed ID: 38515066
[TBL] [Abstract] [Full Text] [Related]
15. TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via β1-integrin/FAK-TAZ-mTOR signaling axis by binding to MYH9.
Hu R; Cao Y; Wang Y; Zhao T; Yang K; Fan M; Guan M; Hou Y; Ying J; Ma X; Deng N; Sun X; Zhang Y; Zhang X
Breast Cancer Res; 2024 Mar; 26(1):48. PubMed ID: 38504374
[TBL] [Abstract] [Full Text] [Related]
16. 5 signature genes revealed by single-cell profiling identified unique immune subtypes affecting the prognosis of ovarian cancer.
Xiang SY; Li QK; Yang Z; Yi Q
Eur Rev Med Pharmacol Sci; 2024 Mar; 28(5):2051-2062. PubMed ID: 38497886
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic evaluation of lymph-vascular space invasion in patients with endometrioid and non-endometrioid endometrial cancer: A multicenter study.
Feng J; Zhang Y; Huang C; Li L; Liu J; Wang J; Guo H; Yao S; Cui Z; Chen G; Gao Q; Sun C; Ma D; Wang B; Li Y; Chu R; Kong B
Eur J Surg Oncol; 2024 Apr; 50(4):108261. PubMed ID: 38484494
[TBL] [Abstract] [Full Text] [Related]
18. Screening by Q Exactive liquid chromatography/tandem mass spectrometry identified Choline, 25-hydroxyvitamin D2, and SM(d18:0/16:1(9Z) (OH)) as biomarkers for high-grade serous ovarian cancer.
Li J; Liu D; Cui M; Wei Z
J Proteomics; 2024 May; 299():105154. PubMed ID: 38471622
[TBL] [Abstract] [Full Text] [Related]
19. Malignant ovarian and testicular germ cell tumors: Common characteristics but different prognoses.
Sköld C; Jansson AK; Glimelius I
J Intern Med; 2024 Jun; 295(6):715-734. PubMed ID: 38468475
[TBL] [Abstract] [Full Text] [Related]
20. RNA m
Liu X; Wei Q; Yang C; Zhao H; Xu J; Mobet Y; Luo Q; Yang D; Zuo X; Chen N; Yang Y; Li L; Wang W; Yu J; Xu J; Liu T; Yi P
Exp Mol Med; 2024 Mar; 56(3):600-615. PubMed ID: 38424195
[TBL] [Abstract] [Full Text] [Related]
[Next]
